Allianz Asset Management GmbH Has $10.32 Million Position in Integra LifeSciences Holdings Corporation (IART)

Allianz Asset Management GmbH lowered its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 30.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 204,492 shares of the life sciences company’s stock after selling 90,589 shares during the quarter. Allianz Asset Management GmbH owned 0.26% of Integra LifeSciences worth $10,323,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Acrospire Investment Management LLC increased its stake in Integra LifeSciences by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after acquiring an additional 1,400 shares during the period. Riverhead Capital Management LLC grew its stake in Integra LifeSciences by 49.9% during the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock worth $131,000 after buying an additional 799 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Integra LifeSciences by 8.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after buying an additional 218 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new stake in Integra LifeSciences during the second quarter worth about $174,000. Finally, Whittier Trust Co. bought a new stake in Integra LifeSciences during the third quarter worth about $169,000. 87.62% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barbara B. Hill bought 10,768 shares of Integra LifeSciences stock in a transaction dated Tuesday, October 31st. The shares were bought at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the transaction, the director now directly owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is currently owned by corporate insiders.

Several analysts have weighed in on IART shares. Jefferies Group reaffirmed a “buy” rating on shares of Integra LifeSciences in a research note on Sunday, September 10th. Barclays reaffirmed an “equal weight” rating and set a $53.00 price objective (up from $47.00) on shares of Integra LifeSciences in a research note on Tuesday, September 12th. Oppenheimer reaffirmed a “buy” rating and set a $60.00 price objective on shares of Integra LifeSciences in a research note on Monday, September 18th. Zacks Investment Research raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $57.00 price objective on the stock in a research note on Tuesday, October 3rd. Finally, J P Morgan Chase & Co cut shares of Integra LifeSciences from an “overweight” rating to a “neutral” rating and set a $44.00 price objective on the stock. in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $53.64.

Integra LifeSciences Holdings Corporation (IART) opened at $50.52 on Friday. Integra LifeSciences Holdings Corporation has a 12-month low of $40.51 and a 12-month high of $56.42. The stock has a market cap of $3,934.86, a P/E ratio of 27.70, a PEG ratio of 2.21 and a beta of 0.65. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences had a return on equity of 16.35% and a net margin of 4.52%. The company had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. During the same quarter in the previous year, the company posted $0.93 earnings per share. Integra LifeSciences’s revenue for the quarter was up 11.4% on a year-over-year basis. research analysts anticipate that Integra LifeSciences Holdings Corporation will post 1.84 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Allianz Asset Management GmbH Has $10.32 Million Position in Integra LifeSciences Holdings Corporation (IART)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://stocknewstimes.com/2017/12/17/allianz-asset-management-gmbh-has-10-32-million-position-in-integra-lifesciences-holdings-corporation-iart.html.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply